Taysha Gene Therapies Inc (TSHA) concluded trading on Thursday at a closing price of $2.41, with 6.68 million shares of worth about $16.09 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 22.34% during that period and on May 01, 2025 the price saw a gain of about 24.23%. Currently the company’s common shares owned by public are about 204.94M shares, out of which, 165.06M shares are available for trading.
Stock saw a price change of 32.42% in past 5 days and over the past one month there was a price change of 90.51%. Year-to-date (YTD), TSHA shares are showing a performance of 39.31% which decreased to -1.63% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.05 but also hit the highest price of $4.32 during that period. The average intraday trading volume for Taysha Gene Therapies Inc shares is 2.09 million. The stock is currently trading 60.48% above its 20-day simple moving average (SMA20), while that difference is up 50.29% for SMA50 and it goes to 25.68% higher than SMA200.
Taysha Gene Therapies Inc (NASDAQ: TSHA) currently have 204.94M outstanding shares and institutions hold larger chunk of about 77.24% of that.
The stock has a current market capitalization of $494.19M and its 3Y-monthly beta is at 0.88. It has posted earnings per share of -$0.38 in the same period. It has Quick Ratio of 5.41 while making debt-to-equity ratio of 0.89. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TSHA, volatility over the week remained 11.41% while standing at 12.16% over the month.
Analysts are in expectations that Taysha Gene Therapies Inc (TSHA) stock would likely to be making an EPS of -0.09 in the current quarter, while forecast for next quarter EPS is -0.09 and it is -0.39 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.1 which is -0.08 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.1 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 3.49% while it is estimated to decrease by -20.45% in next year. EPS is likely to grow at an annualized rate of 8.17% for next 5-years, compared to annual growth of -63.99% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BMO Capital Markets on June 27, 2024 offering an Outperform rating for the stock and assigned a target price of $5 to it. Coverage by Piper Sandler stated Taysha Gene Therapies Inc (TSHA) stock as an Overweight in their note to investors on April 09, 2024, suggesting a price target of $9 for the stock. On February 01, 2023, Jefferies Downgrade their recommendations, while on January 27, 2023, Morgan Stanley Downgrade their ratings for the stock with a price target of $3. Stock get a Neutral rating from Goldman on November 09, 2022.
